Center for Reproductive Health Research Studies

If you are unsure about what studies you qualify for, simply email us at [email protected]. Alternatively, explore different UCSF studies at clinicaltrials.ucsf.edu

I'm interested in participating!

Fertility Preservation Studies

BRIOR Study | Impact of Local Radiotherapy to the Breast on Ovarian Reserve in Premenopausal Women with Early-Stage Breast Cancer

Status: Active, Enrolling
This study aims to prospectively assess the impact of distant effects from breast radiation on ovarian reserve. We will determine ovarian reserve through blood measurements of Anti-Müllerian Hormone (AMH), a relatively new and reliable serum biomarker of ovarian reserve that has already been incorporated into the standard practice of reproductive endocrinology and infertility.

You may be eligible if you are: female (or assigned female at birth), aged 18-45, and diagnosed with in-situ breast cancer or stage 1 breast cancer

Nik Lenhart
Clinical Research Coordinator
415-502-2555
[email protected]

Mitchell Rosen MD HCLD
Principal Investigator

GEAR Study | Gender Expansive Attitudes about Reproductive Health Study

Status: Active, Enrolling
Currently, there are few studies (and none in the United States) that seek to describe the impact of expanding fertility services on the transgender community and their quality of life. The GEAR study will be one of the first of its kind to explore the impact of fertility options on quality of life among transgender, non-binary, and non-conforming people.

You may be eligible if you are: you identify as transgender or gender non-binary, and aged 18 years or older

 

Amanda Adeleye
Principal Invesitgator
[email protected]

Study Website

 

 


TALES Trial | Fertility Preservation using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial

Status: Active, Enrolling
Letrozole plus gonadotropin, and Tamoxifen plus gonadotropin, are two methods currently used worldwide in ovarian stimulation cycles for fertility preservation in patients with estrogen-receptor-positive breast cancer. Improved knowledge about the efficacy of these medications, with regard to oocyte yield, has the potential to significantly improve quality of life in reproductive-age breast cancer survivors.

You may be eligible if you are: female (or assigned female at birth), aged 18 years and older, diagnosed with breast cancer and not currently receiving chemotherapy

Nik Lenhart
Clinical Research Coordinator
415-502-2555
[email protected]

Mitchell Rosen MD HCLD
Principal Investigator

clinical trials Website